6/27/17 Red Screen Day: Sell-Off in Biotechs Possibly Due to Senate Delay in Healthcare Vote IBB down 1.54% at $314.80. Momentum stocks are weak; NASDAQ down 1.2%. Take profits on XBI trade at $78 range after 34% move YTD. Allow time for arm twisting by Republicans after JY 4. ======== Biotech Breakout Continues with Larger […]
ASCO Update: Many Stocks Rallied on the News Over the Past Month ASCO Rally is Holding but Fails to Break Through to New 2017 Highs The stock performance of most companies with ASCO news is summarized below.Biotechnology stocks are driven by clinical and deal news so here are some trends to consider: Anticipation of positive […]
Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone? Technicals Matter Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of the biotech ETFs. Large cap tech stocks rule. The large cap centric […]
Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at $287.67 breaking the $290 technical level not seen since […]
Top Biopharmaceutical Stocks : Performance and Financial Metrics after 2016 Earnings We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in mid-February 2016. But the […]
Trump Biotech Rally-Have a Balanced Portfolio Everybody who invests in biotech knows there has been a Trump biotech rally since his election as you can see from the chart and data below. Many opinions and analysis were given for the rally.Some pundits say it is because the end of the grueling election has removed […]
Rayno Life Science… Special Report #1: Hot Biotech Stocks in 2016 Biotech stocks have been in a funk for most of 2016 and then got absolutely crushed in October. The underlying causes are well-known among them bad news from bad actors like Mylan and Turing, the populist revolt against high drug prices and lackluster top […]
Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have been taken down because price increases are not likely for 2017 . Another […]
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson (MCK). All large caps are red except Alexion (ALXN) up 1.83%. Abbvie (ABBV) down 6% on revenue miss;Humira […]
Update-2…Market rallies Monday after 2% sell-off on Friday IBB held support at $280, up 1.9% today to 284 as of mid-morning . Mid-caps and large caps strong. —— Update-1… FED Rate Increase Fear Sparks Sell-Off NASDAQ down 1.14%, 10 Year Bond 1.67%, IBB down 1.4%, XBI down 1.64%… 11:30 am EDT. European bonds are also in a […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.